
Alelion - Impressive cost reductions and on the verge of series production

Redeye believes Alelion reported undramatic Q3'20 figures. Sales declined y-o-y due to previously announced reasons, and slightly lower production activity than anticipated due to Covid-19. We believe this is more of a short-term timing effect rather than a long-term issue. Furthermore, very impressive cost reductions were reported, lowering y-o-y OPEX significantly.

Read more and download the Research Update

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Alelion - Impressive cost reductions and on the verge of series production